FDA EIR - PolyPeptide Laboratories Private Limited - August 11, 2016

An FDA inspection of Polypeptide Laboratories Pvt Ltd, located in Ambernath (east) Thane district, was conducted from August 8 to August 11, 2016. The inspection assessed the company's operations as a manufacturer of human and animal drugs, falling under the regulatory oversight of the Food and Drug Administration's framework for drug manufacturing. Despite the inspection, the FDA concluded with a "No Action Indicated" (NAI) status, indicating that no formal regulatory actions were required from the company based on the findings.

However, the inspection itself was internally noted as deficient. A significant issue highlighted was the insufficient documentation of four verbal observations, which were identified as potential FDA-483 items. An FDA-483 form details observed conditions that may constitute violations of the Food, Drug, and Cosmetic Act. While these potential issues were noted, they were not formally documented or reported adequately to result in specific findings or direct corrective actions for Polypeptide Laboratories at that time. Consequently, the primary concern was with the inspection's thoroughness rather than confirmed regulatory violations by the firm. The report suggested an internal recommendation to perform a re-inspection due to these procedural shortcomings.